Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Susana Banerjee, MBBS, MA, FRCP, PhD

Consultant Medical Oncologist
Research Lead Gynecological Cancers
The Royal Marsden NHS Foundation Trust
Reader in Women's Cancers
The Institute of Cancer Research
London, United Kingdom

Disclosures

Susana Banerjee, MBBS, MA, FRCP, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen; AstraZeneca; Epsilogen (not financially renumerated); Genmabs; GlaxoSmithKline; Immunogen; Merck Sharp & Dohme; Merck Sereno; Mersana; Oncxerna; Pfizer; Roche; Shattuck Labs
Speaker or member of speakers bureau for: Amgen; AstraZeneca; Clovis; GlaxoSmithKline; Immunogen; Merck Sharp & Dohme; Mersana; Pfizer; Takeda
Research funding from: AstraZeneca; GlaxoSmithKline

Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Disclosures

Alexandra Leary, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: All fees to the institution: Ability; AstraZeneca; Clovis; GlaxoSmithKline; Merck Sharp & Dohme
Research funding from: Agenus; AstraZeneca; GlaxoSmithKline; Iovance; Merck Sharp & Dohme; Pfizer; Roche; Zentalis

Isabelle Ray-Coquard, MD, PhD

Medical Oncologist
Centre Leon Bérard
Université Claude Bernard
Lyon, France

Disclosures

Isabelle Ray-Coquard, MD, PhD, has no relevant financial relationships.

Editors

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Keisha Peters , MSc, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME

Essential Updates in Ovarian Cancer From Paris 2022

Authors: Susana Banerjee, MBBS, MA, FRCP, PhD; Alexandra Leary, MD, PhD; Isabelle Ray-Coquard, MD, PhD
CME Released: 10/4/2022
Valid for credit through: 10/4/2023

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for non-US hematologists/oncologists, obstetricians & gynecologists, surgeons, nurses, nurse practitioners, and others involved in the care of patients with ovarian cancer.

The goal of this activity is for learners to be better able to highlight the latest clinical data in ovarian cancer presented in Paris 2022.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Emerging clinical trial data presented on emerging therapies in ovarian cancer
- Patient management implications of the latest trial data in ovarian cancer
Demonstrate greater confidence in their ability to
- Understand the role of molecular pathology and diagnostics in the management of ovarian cancer

Disclosures

Faculty

Susana Banerjee, MBBS, MA, FRCP, PhD

Consultant Medical Oncologist
Research Lead Gynecological Cancers
The Royal Marsden NHS Foundation Trust
Reader in Women's Cancers
The Institute of Cancer Research
London, United Kingdom

Disclosures

Susana Banerjee, MBBS, MA, FRCP, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen; AstraZeneca; Epsilogen (not financially renumerated); Genmabs; GlaxoSmithKline; Immunogen; Merck Sharp & Dohme; Merck Sereno; Mersana; Oncxerna; Pfizer; Roche; Shattuck Labs
Speaker or member of speakers bureau for: Amgen; AstraZeneca; Clovis; GlaxoSmithKline; Immunogen; Merck Sharp & Dohme; Mersana; Pfizer; Takeda
Research funding from: AstraZeneca; GlaxoSmithKline

Alexandra Leary, MD, PhD

Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Disclosures

Alexandra Leary, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: All fees to the institution: Ability; AstraZeneca; Clovis; GlaxoSmithKline; Merck Sharp & Dohme
Research funding from: Agenus; AstraZeneca; GlaxoSmithKline; Iovance; Merck Sharp & Dohme; Pfizer; Roche; Zentalis

Isabelle Ray-Coquard, MD, PhD

Medical Oncologist
Centre Leon Bérard
Université Claude Bernard
Lyon, France

Disclosures

Isabelle Ray-Coquard, MD, PhD, has no relevant financial relationships.

Editors

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Keisha Peters , MSc, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CME

Essential Updates in Ovarian Cancer From Paris 2022

Authors: Susana Banerjee, MBBS, MA, FRCP, PhD; Alexandra Leary, MD, PhD; Isabelle Ray-Coquard, MD, PhDFaculty and Disclosures

CME Released: 10/4/2022

Valid for credit through: 10/4/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

New Data Presented at Paris 2022 on Established Therapies in Ovarian Cancer and Their Clinical Implications

Dr Ray-Coquard discusses the latest data in and the possible implications of this these findings, including the ARIEL4 and MEDIOLA studies.
Isabelle Ray-Coquard, MD, PhD

Recent Data With PARP Inhibitors in First Line and Beyond

Join Dr Banerjee as she summarizes recent data on poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer from Paris 2022.
Susana Banerjee, MBBS, MA, FRCP, PhD

Early and Emerging Clinical Data in Ovarian Cancer: Opportunities With Immunomodulation

Dr Leary gives an overview of the latest clinical data available on these emerging therapies.
Alexandra Leary, MD, PhD

Bringing It All Together -- Making the Best of PARP Inhibitor Therapy: When, Who, and How

Dr Ray-Coquard and Dr Banerjee discuss the changing role of PARP inhibitors in ovarian cancer based on the findings presented at Paris 2022.
Susana Banerjee, MBBS, MA, FRCP, PhD; Isabelle Ray-Coquard, MD, PhD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 7

CME Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Faculty

Susana Banerjee, MBBS, MA, FRCP, PhD

Alexandra Leary, MD, PhD

Isabelle Ray-Coquard, MD, PhD

Editors

Keisha Peters, MSc

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME

Essential Updates in Ovarian Cancer From Paris 2022

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Susana Banerjee, MBBS, MA, FRCP, PhD

Alexandra Leary, MD, PhD

Isabelle Ray-Coquard, MD, PhD

Editors

Keisha Peters, MSc

Eloise Ballard, PhD

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Essential Updates in Ovarian Cancer From Paris 2022

Contents of This CPD Activity

New Data Presented at Paris 2022 on Established Therapies in Ovarian Cancer and Their Clinical Implications

Recent Data With PARP Inhibitors in First Line and Beyond

Early and Emerging Clinical Data in Ovarian Cancer: Opportunities With Immunomodulation

Bringing It All Together -- Making the Best of PARP Inhibitor Therapy: When, Who, and How

Learning Feedback Questions